Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Cemiplimab + Ipilimumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cemiplimab||Libtayo||REGN2810|SAR439684||Immune Checkpoint Inhibitor 148 PD-L1/PD-1 antibody 93||Libtayo (cemiplimab) is a human antibody that targets PD-1 (PDCD1) and prevents interaction with PD-L1 (CD274) and PD-L2 (PDCD1LG2), potentially resulting in increased anti-tumor immune response and decreased tumor growth (PMID: 28265006). Libtayo (cemiplimab) is FDA approved for use in patients with cutaneous squamous cell carcinoma, who are not not eligible for curative surgery or radiation, in patients with locally advanced or metastatic basal cell carcinoma who have received or are not eligible for a hedgehog pathway inhibitor, and as first-line treatment in patients with advanced non-small cell lung cancer with high PD-L1 expression (TPS>=50%) and no EGFR, ALK, or ROS1 aberrations (FDA.gov).|
|Ipilimumab||Yervoy||BMS-734016||CTLA4 Antibody 22 Immune Checkpoint Inhibitor 148||Yervoy (ipilimumab) is an antibody that binds to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), causing increased T-cell activation (PMID: 28891423). Yervoy (ipilimumab) is FDA approved for use in patients with metastatic melanoma, including patients 12 years or older, and in combination with Opdivo (nivolumab) for intermediate or poor-risk renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (including patients 12 years or older), hepatocellular carcinoma previously treated with Nexavar (sorafenib), in combination with Opdivo (nivolumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic non-small cell lung cancer without EGFR or ALK alterations, and in combination with Opdivo (nivolumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent non-small cell lung cancer without EGFR or ALK alterations (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03430063||Phase II||Cemiplimab + Ipilimumab Cemiplimab||A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer||Completed||USA | FRA | ESP | DEU | BEL||4|
|NCT03409614||Phase III||Cemiplimab + Ipilimumab Cemiplimab||Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer||Active, not recruiting||USA | ITA | FRA | AUT||14|
|NCT03515629||Phase III||Cemiplimab + Ipilimumab Pembrolizumab||REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer||Completed||USA | ITA||1|
|NCT03477864||Phase I||Ipilimumab Cemiplimab + Ipilimumab Cemiplimab||Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer||Withdrawn||0|